In order to keep competitive, pharma firms and their partners must keep current with the latest developments in drug delivery.
Watch Now
Business-review-webinars
Current drug development strategies are very expensive and lead to high drug attrition rates. One major reason for low success rates is the lack of predictive preclinical models for efficacy testing. The availability of induced pluripotent stem cell (hiPSC) technologies holds great promise to bring human biology to drug discovery but is still compromised by problems related to scalability, biological relevance, robustness and costs.
Watch Now
biopharma-asia
The Pharmaceutical Industry has a strong need to develop knowledge from data. Although the latter is not at a premium in the Pharmaceutical Industry the former is, as always, at a premium. Multivariate data analysis (MVA) is a set of statistical data analytical methods which has been widely adopted within the Pharmaceutical Industry, and it has pre-eminence within the discipline.
Watch Now
Ambry Genetics
In this webinar, Dr. Xu will summarize recent data on inherited risk for prostate cancer, including germline mutations in high-penetrance genes (HPGs), risk-associated SNPs, and SNP-based genetic risk score (GRS). He will present detailed data supporting the broad-sense validity of GRS in risk assessment as well as the need for assessing the narrow-sense validity of GRS values. Finally, he will review the data supporting the importance of GRS when estimating the penetrance of HPGs.
Watch Now